

Ranbaxy Pharmaceuticals Proprietary Limited
(Registration number 1993/003111/07)
Financial statements
for the year ended 31 March 2022

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

General Information

Country of incorporation and domicile	South Africa
Nature of business and principal activities	Import, marketing, manufacturing and trade of pharmaceutical goods and services
Directors	Desmond William Brothers Umesh Kumar Maini Avesh Ajoodha Deepakh Mangal Sewnarain
Registered office	14 Lautre Road Stormill Ext 1 Roodepoort Gauteng 1724
Business address	14 Lautre Road Stormill Ext 1 Roodepoort Gauteng 1724
Postal address	P O Box 43486 Industria Gauteng 2042
Auditor	Ernst & Young Inc. 102 Rivonia Road Dennehof Sandton 2196
Secretary	SNG Grant Thornton
Company registration number	1993/003111/07
Level of assurance	These financial statements have been audited in compliance with the applicable requirements of the Companies Act of South Africa.
Preparer	The financial statements were independently compiled by: Melissa McGill CA(SA)
Issued	06 May 2022

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Contents

	Page
Directors' Responsibilities and Approval	3
Directors' Report	4 - 5
Independent Auditor's Report	6 - 8
Statement of Financial Position	9
Statement of Profit or Loss and Other Comprehensive Income	10
Statement of Changes in Equity	11
Statement of Cash Flows	12
Accounting Policies	13 - 22
Notes to the Financial Statements	23 - 36

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Directors' Responsibilities and Approval

The directors are required in terms of the Companies Act of South Africa to maintain adequate accounting records and are responsible for the content and integrity of the financial statements and related financial information included in this report. It is their responsibility to ensure that the financial statements fairly present the state of affairs of the company as at the end of the financial year and the results of its operations and cash flows for the period then ended, in conformity with International Financial Reporting Standards. The external auditor is engaged to express an independent opinion on the financial statements.

The financial statements are prepared in accordance with International Financial Reporting Standards and are based upon appropriate accounting policies consistently applied and supported by reasonable and prudent judgements and estimates.

The directors acknowledge that they are ultimately responsible for the system of internal financial control established by the company and place considerable importance on maintaining a strong control environment. To enable the directors to meet these responsibilities, the board of directors sets standards for internal control aimed at reducing the risk of error or loss in a cost effective manner. The standards include the proper delegation of responsibilities within a clearly defined framework, effective accounting procedures and adequate segregation of duties to ensure an acceptable level of risk. These controls are monitored throughout the company and all employees are required to maintain the highest ethical standards in ensuring the company's business is conducted in a manner that in all reasonable circumstances is above reproach. The focus of risk management in the company is on identifying, assessing, managing and monitoring all known forms of risk across the company. While operating risk cannot be fully eliminated, the company endeavours to minimise it by ensuring that appropriate infrastructure, controls, systems and ethical behaviour are applied and managed within predetermined procedures and constraints.

The directors are of the opinion, based on the information and explanations given by management, that the system of internal control provides reasonable assurance that the financial records may be relied on for the preparation of the financial statements. However, any system of internal financial control can provide only reasonable, and not absolute, assurance against material misstatement or loss.

The directors have reviewed the company's cash flow forecast for the year to 31 March 2023 and, in light of this review and the current financial position, they are satisfied that the company has or had access to adequate resources to continue in operational existence for the foreseeable future.

The external auditor is responsible for independently auditing and reporting on the company's financial statements. The financial statements have been examined by the company's external auditor and their report is presented on pages 6 to 8.

The financial statements set out on pages 9 to 36, which have been prepared on the going concern basis, were approved by the board of directors on 06 May 2022 and were signed on their behalf by:

Avesh Ajoodha

Desmond William Brothers

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Directors' Report

The directors have pleasure in submitting their report on the financial statements of Ranbaxy Pharmaceuticals Proprietary Limited for the year ended 31 March 2022.

1. Nature of business

Ranbaxy Pharmaceuticals Proprietary Limited was incorporated in South Africa with interests in the industry. The company operates in South Africa, rest of Africa and Europe.

There have been no material changes to the nature of the company's business from the prior year.

2. Review of financial results and activities

The financial statements have been prepared in accordance with International Financial Reporting Standards and the requirements of the Companies Act of South Africa. The accounting policies have been applied consistently compared to the prior year.

Full details of the financial position, results of operations and cash flows of the company are set out in these financial statements.

3. Share capital

There have been no changes to the authorised or issued share capital during the year under review.

4. Dividends

No dividends were declared or paid in the current year (2021: Rnil).

5. Directorate

The directors in office at the date of this report are as follows:

Directors

Desmond William Brothers

Umesh Kumar Maini

Avesh Ajoodha

Deepakh Mangal Sewnarain

6. Events after the reporting period

The directors are not aware of any material event which occurred after the reporting date and up to the date of this report.

7. Going concern

The financial statements have been prepared on the basis of accounting policies applicable to a going concern. This basis presumes that funds will be available to finance future operations and that the realisation of assets and settlement of liabilities, contingent obligations and commitments will occur in the ordinary course of business.

The directors believe that the company has adequate financial resources to continue in operation for the foreseeable future and accordingly the financial statements have been prepared on a going concern basis. The directors have satisfied themselves that the company is in a sound financial position and that it has access to sufficient borrowing facilities to meet its foreseeable cash requirements. The directors are not aware of any new material changes that may adversely impact the company. The directors are also not aware of any material non-compliance with statutory or regulatory requirements or of any pending changes to legislation which may affect the company.

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Directors' Report

8. Auditors

Ernst & Young Inc. continued in office as auditors for the company for 2022.

9. Secretary

The company secretary is Grant Thornton.

Independent Auditor's Report

To the Shareholder of Ranbaxy Pharmaceuticals Proprietary Limited

Opinion

I have audited the financial statements of Ranbaxy Pharmaceuticals Proprietary Limited (the company) set out on pages 9 to 36, which comprise the statement of financial position as at 31 March 2022, statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In my opinion, the financial statements present fairly, in all material respects, the financial position of Ranbaxy Pharmaceuticals Proprietary Limited as at 31 March 2022, and its financial performance and cash flows for the year then ended in accordance with International Financial Reporting Standards and the requirements of the Companies Act of South Africa.

Basis for Opinion

I conducted my audit in accordance with International Standards on Auditing. My responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of my report. I am independent of the company in accordance with the Independent Regulatory Board for Auditors' Code of Professional Conduct for Registered Auditors (IRBA Code) and other independence requirements applicable to performing audits of financial statements in South Africa. I have fulfilled my other ethical responsibilities in accordance with the IRBA Code and in accordance with other ethical requirements applicable to performing audits in South Africa. The IRBA Code is consistent with the corresponding sections of the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards). I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the document titled "Ranbaxy Pharmaceuticals Proprietary Limited financial statements for the year ended 31 March 2022", which includes the Directors' Report as required by the Companies Act of South Africa. The other information does not include the financial statements and my auditor's report thereon.

My opinion on the financial statements does not cover the other information and I do not express an audit opinion or any form of assurance conclusion thereon.

In connection with my audit of the financial statements, my responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or my knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work I have performed, I conclude that there is a material misstatement of this other information, I am required to report that fact. I have nothing to report in this regard.

Independent Auditor's Report

Responsibilities of the Directors for the Financial Statements

The directors are responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Reporting Standards and the requirements of the Companies Act of South Africa, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Independent Auditor's Report

Auditor's Responsibilities for the Audit of the Financial Statements

My objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with International Standards on Auditing, I exercise professional judgement and maintain professional scepticism throughout the audit. I also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify my opinion. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

I communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

Ernst & Young Inc.
Partner

Registered Auditors

06 May 2022

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Statement of Financial Position as at 31 March 2022

	Notes	2022 R	2021 R
Assets			
Non-Current Assets			
Property, plant and equipment	3	76 358 119	75 247 808
Right-of-use assets	4	1 960 492	2 495 172
Intangible assets	5	449 959	458 794
		78 768 570	78 201 774
Current Assets			
Inventories	7	443 475 346	539 419 684
Trade and other receivables	8	295 488 473	398 509 407
Cash and cash equivalents	9	190 592 873	98 667 166
		929 556 692	1 036 596 257
Total Assets		1 008 325 262	1 114 798 031
Equity and Liabilities			
Equity			
Share capital	10	700 000 200	700 000 200
Accumulated loss		(219 919 260)	(273 902 548)
		480 080 940	426 097 652
Liabilities			
Non-Current Liabilities			
Lease liabilities	4	1 655 936	2 134 560
Current Liabilities			
Trade and other payables	11	526 109 764	686 153 671
Lease liabilities	4	478 622	412 148
		526 588 386	686 565 819
Total Liabilities		528 244 322	688 700 379
Total Equity and Liabilities		1 008 325 262	1 114 798 031

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Statement of Profit or Loss and Other Comprehensive Income

	Notes	2022 R	2021 R
Revenue	12	1 399 830 554	1 171 245 545
Cost of sales	13	(1 079 017 648)	(856 104 960)
Gross profit		320 812 906	315 140 585
Other operating income	14	10 692 905	3 938 696
Other operating gains (losses)	15	(752 430)	2 078 811
Other operating expenses		(278 632 540)	(292 323 463)
Operating profit	16	52 120 841	28 834 629
Investment income	17	2 248 391	1 899 218
Finance costs	18	(385 941)	(1 681)
Total comprehensive income for the year		53 983 291	30 732 166

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Statement of Changes in Equity

	Share capital	Redeemable preference shares	Total share capital	Accumulated loss	Total equity
	R	R	R	R	R
Balance at 01 April 2020	200 000 200	500 000 000	700 000 200	(304 634 714)	395 365 486
Total comprehensive income for the year	-	-	-	30 732 166	30 732 166
Balance at 01 April 2021	200 000 200	500 000 000	700 000 200	(273 902 551)	426 097 649
Total comprehensive income for the year	-	-	-	53 983 291	53 983 291
Balance at 31 March 2022	200 000 200	500 000 000	700 000 200	(219 919 260)	480 080 940
Note	10	10	10		

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Statement of Cash Flows

	Notes	2022 R	2021 R
Cash flows from operating activities			
Cash generated from operations	20	100 425 017	62 387 200
Interest income		2 248 391	1 899 218
Finance costs		(385 941)	(1 681)
Net cash from operating activities		102 287 467	64 284 737
Cash flows from investing activities			
Purchase of property, plant and equipment	3	(9 908 213)	(20 511 218)
Purchase of other intangible assets	5	(41 397)	-
Net cash from investing activities		(9 949 610)	(20 511 218)
Cash flows from financing activities			
Payment on lease liabilities		(412 150)	(304 921)
Net cash from financing activities		(412 150)	(304 921)
Total cash movement for the year		91 925 707	43 468 598
Cash at the beginning of the year		98 667 166	55 198 568
Total cash at end of the year	9	190 592 873	98 667 166

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Accounting Policies

1. Significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below.

1.1 Basis of preparation

The financial statements have been prepared on the going concern basis in accordance with, and in compliance with, International Financial Reporting Standards ("IFRS") and International Financial Reporting Interpretations Committee ("IFRIC") interpretations issued and effective at the time of preparing these financial statements and the Companies Act of South Africa of South Africa, as amended.

These financial statements comply with the requirements of the SAICA Financial Reporting Guides as issued by the Accounting Practices Committee and the Financial Reporting Pronouncements as issued by the Financial Reporting Standards Council.

The financial statements have been prepared on the historic cost convention, unless otherwise stated in the accounting policies which follow and incorporate the principal accounting policies set out below. They are presented in Rands, which is the company's functional currency.

These accounting policies are consistent with the previous period.

1.2 Significant judgements and sources of estimation uncertainty

The preparation of financial statements in conformity with IFRS requires management, from time to time, to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. These estimates and associated assumptions are based on experience and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Key sources of estimation uncertainty

Impairment of financial assets

The impairment provisions for financial assets are based on assumptions about risk of default and expected loss rates. The company uses judgement in making these assumptions and selecting the inputs to the impairment calculation, based on the company's past history, existing market conditions as well as forward looking estimates at the end of each reporting period. For details of the key assumptions and inputs used, refer to the individual notes addressing financial assets.

Allowance for slow moving, damaged and obsolete inventory

Management assesses whether inventory is impaired by comparing its cost to its estimated net realisable value. Where an impairment is necessary, inventory items are written down to net realisable value. The write down is included in cost of sales.

Impairment testing

The company reviews and tests the carrying value of assets when events or changes in circumstances suggest that the carrying amount may not be recoverable. When such indicators exist, management determine the recoverable amount by performing value in use and fair value calculations. These calculations require the use of estimates and assumptions. When it is not possible to determine the recoverable amount for an individual asset, management assesses the recoverable amount for the cash generating unit to which the asset belongs.

Useful lives of property, plant and equipment

Management assess the appropriateness of the useful lives of property, plant and equipment at the end of each reporting period. The useful lives of motor vehicles, furniture and computer equipment are determined based on company replacement policies for the various assets. Individual assets within these classes, which have a significant carrying amount are assessed separately to consider whether replacement will be necessary outside of normal replacement parameters. The useful life of manufacturing equipment is assessed annually based on factors including wear and tear, technological obsolescence and usage requirements.

When the estimated useful life of an asset differs from previous estimates, the change is applied prospectively in the determination of the depreciation charge.

1.3 Property, plant and equipment

Property, plant and equipment are tangible assets which the company holds for its own use or for rental to others and which are expected to be used for more than one year.

An item of property, plant and equipment is recognised as an asset when it is probable that future economic benefits associated with the item will flow to the company, and the cost of the item can be measured reliably.

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Accounting Policies

1.3 Property, plant and equipment (continued)

Property, plant and equipment is initially measured at cost. Cost includes all of the expenditure which is directly attributable to the acquisition or construction of the asset, including the capitalisation of borrowing costs on qualifying assets and adjustments in respect of hedge accounting, where appropriate.

Expenditure incurred subsequently for major services, additions to or replacements of parts of property, plant and equipment are capitalised if it is probable that future economic benefits associated with the expenditure will flow to the company and the cost can be measured reliably. Day to day servicing costs are included in profit or loss in the year in which they are incurred.

Property, plant and equipment is subsequently stated at cost less accumulated depreciation and any accumulated impairment losses, except for land which is stated at cost less any accumulated impairment losses.

Depreciation of an asset commences when the asset is available for use as intended by management. Depreciation is charged to write off the asset's carrying amount over its estimated useful life to its estimated residual value, using a method that best reflects the pattern in which the asset's economic benefits are consumed by the company. Leased assets are depreciated in a consistent manner over the shorter of their expected useful lives and the lease term. Depreciation is not charged to an asset if its estimated residual value exceeds or is equal to its carrying amount. Depreciation of an asset ceases at the earlier of the date that the asset is classified as held for sale or derecognised.

The useful lives of items of property, plant and equipment have been assessed as follows:

Item	Depreciation method	Average useful life
Machinery	Straight line	5 - 25 years
Fixtures and fittings	Straight line	6 years
Motor vehicles	Straight line	5 years
Office equipment	Straight line	6 years
Computer equipment	Straight line	3 years
Construction in progress	Straight line	10% - 33.33% per annum
Leasehold improvements	Straight line	10% - 33.33% per annum

The residual value, useful life and depreciation method of each asset are reviewed at the end of each reporting year. If the expectations differ from previous estimates, the change is accounted for prospectively as a change in accounting estimate.

Each part of an item of property, plant and equipment with a cost that is significant in relation to the total cost of the item is depreciated separately.

The depreciation charge for each year is recognised in profit or loss unless it is included in the carrying amount of another asset.

Impairment tests are performed on property, plant and equipment when there is an indicator that they may be impaired. When the carrying amount of an item of property, plant and equipment is assessed to be higher than the estimated recoverable amount, an impairment loss is recognised immediately in profit or loss to bring the carrying amount in line with the recoverable amount.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its continued use or disposal. Any gain or loss arising from the derecognition of an item of property, plant and equipment, determined as the difference between the net disposal proceeds, if any, and the carrying amount of the item, is included in profit or loss when the item is derecognised.

1.4 Intangible assets

An intangible asset is recognised when:

- it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity; and
- the cost of the asset can be measured reliably.

Intangible assets are initially recognised at cost.

Expenditure on research (or on the research phase of an internal project) is recognised as an expense when it is incurred.

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Accounting Policies

1.4 Intangible assets (continued)

An intangible asset arising from development (or from the development phase of an internal project) is recognised when:

- it is technically feasible to complete the asset so that it will be available for use or sale.
- there is an intention to complete and use or sell it.
- there is an ability to use or sell it.
- it will generate probable future economic benefits.
- there are available technical, financial and other resources to complete the development and to use or sell the asset.
- the expenditure attributable to the asset during its development can be measured reliably.

Intangible assets are carried at cost less any accumulated amortisation and any impairment losses.

An intangible asset is regarded as having an indefinite useful life when, based on all relevant factors, there is no foreseeable limit to the period over which the asset is expected to generate net cash inflows. Amortisation is not provided for these intangible assets, but they are tested for impairment annually and whenever there is an indication that the asset may be impaired. For all other intangible assets amortisation is provided on a straight line basis over their useful life.

The amortisation period and the amortisation method for intangible assets are reviewed every period-end.

Reassessing the useful life of an intangible asset with a finite useful life after it was classified as indefinite is an indicator that the asset may be impaired. As a result the asset is tested for impairment and the remaining carrying amount is amortised over its useful life.

Internally generated brands, mastheads, publishing titles, customer lists and items similar in substance are not recognised as intangible assets.

Amortisation is provided to write down the intangible assets, on a straight line basis, to their residual values as follows:

Item	Depreciation method	Average useful life
Computer software	Straight line	2 years
Copyrights, patents and other industrial property rights, service and operating rights	Straight line	5 years

1.5 Financial instruments

Financial instruments held by the company are classified in accordance with the provisions of IFRS 9 Financial Instruments.

Broadly, the classification possibilities, which are adopted by the company, as applicable, are as follows:

Financial assets which are equity instruments:

- Mandatorily at fair value through profit or loss; or
- Designated as at fair value through other comprehensive income. (This designation is not available to equity instruments which are held for trading or which are contingent consideration in a business combination).

Financial assets which are debt instruments:

- Amortised cost. (This category applies only when the contractual terms of the instrument give rise, on specified dates, to cash flows that are solely payments of principal and interest on principal, and where the instrument is held under a business model whose objective is met by holding the instrument to collect contractual cash flows); or
- Fair value through other comprehensive income. (This category applies only when the contractual terms of the instrument give rise, on specified dates, to cash flows that are solely payments of principal and interest on principal, and where the instrument is held under a business model whose objective is achieved by both collecting contractual cash flows and selling the instruments); or
- Mandatorily at fair value through profit or loss. (This classification automatically applies to all debt instruments which do not qualify as at amortised cost or at fair value through other comprehensive income); or
- Designated at fair value through profit or loss. (This classification option can only be applied when it eliminates or significantly reduces an accounting mismatch).

Derivatives which are not part of a hedging relationship:

- Mandatorily at fair value through profit or loss.

Financial liabilities:

- Amortised cost; or
- Mandatorily at fair value through profit or loss. (This applies to contingent consideration in a business combination or to liabilities which are held for trading); or
- Designated at fair value through profit or loss. (This classification option can be applied when it eliminates or significantly reduces an accounting mismatch; the liability forms part of a group of financial instruments managed on a fair value basis; or it forms part of a contract containing an embedded derivative and the entire contract is designated as at fair value through profit or loss).

Note 23 Financial instruments and risk management presents the financial instruments held by the company based on their specific classifications.

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Accounting Policies

1.5 Financial instruments (continued)

All regular way purchases or sales of financial assets are recognised and derecognised on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace.

The specific accounting policies for the classification, recognition and measurement of each type of financial instrument held by the company are presented below:

Trade and other receivables

Classification

Trade and other receivables, excluding, when applicable, VAT and prepayments, are classified as financial assets subsequently measured at amortised cost (note 8).

They have been classified in this manner because their contractual terms give rise, on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding, and the company's business model is to collect the contractual cash flows on trade and other receivables.

Recognition and measurement

Trade and other receivables are recognised when the company becomes a party to the contractual provisions of the receivables. They are measured, at initial recognition, at fair value plus transaction costs, if any.

They are subsequently measured at amortised cost.

The amortised cost is the amount recognised on the receivable initially, minus principal repayments, plus cumulative amortisation (interest) using the effective interest method of any difference between the initial amount and the maturity amount, adjusted for any loss allowance.

Application of the effective interest method

For receivables which contain a significant financing component, interest income is calculated using the effective interest method, and is included in profit or loss in investment income (note 17).

The application of the effective interest method to calculate interest income on trade receivables is dependent on the credit risk of the receivable as follows:

- The effective interest rate is applied to the gross carrying amount of the receivable, provided the receivable is not credit impaired. The gross carrying amount is the amortised cost before adjusting for a loss allowance.
- If a receivable is purchased or originated as credit-impaired, then a credit-adjusted effective interest rate is applied to the amortised cost in the determination of interest. This treatment does not change over the life of the receivable, even if it is no longer credit-impaired.
- If a receivable was not purchased or originally credit-impaired, but it has subsequently become credit-impaired, then the effective interest rate is applied to the amortised cost of the receivable in the determination of interest. If, in subsequent periods, the receivable is no longer credit impaired, then the interest calculation reverts to applying the effective interest rate to the gross carrying amount.

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Accounting Policies

1.5 Financial instruments (continued)

Impairment

A forward looking allowance for expected credit losses is recognised for all debt instruments not held at fair value through profit or loss. Expected credit losses are based on the difference between contractual cash flows due in accordance with the contract and all the cash flows that the company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

The impairment methodology applied depends on whether there has been a significant increase in credit risk:

- For credit exposures with no significant increase in credit risk since initial recognition, expected credit losses are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month expected credit loss).
- For credit exposures with no significant increase in credit risk since initial recognition, expected credit losses are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month expected credit loss).

For trade receivables and contract assets, a simplified approach is applied in calculating expected credit losses. Instead of tracking changes in credit risk, a loss allowance is recognised based on lifetime expected credit losses at each reporting date. A provision matrix was established that is based on the company's historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

Measurement and recognition of expected credit losses

An impairment gain or loss is recognised in profit or loss with a corresponding adjustment to the carrying amount of trade and other receivables, through use of a loss allowance account. The impairment loss is included in other operating expenses in profit or loss as a movement in credit loss allowance (note 16).

Write off policy

The company writes off a receivable when there is information indicating that the counterparty is in severe financial difficulty and there is no realistic prospect of recovery, e.g. when the counterparty has been placed under liquidation or has entered into bankruptcy proceedings. Receivables written off may still be subject to enforcement activities under the company recovery procedures, taking into account legal advice where appropriate. Any recoveries made are recognised in profit or loss.

Trade and other payables

Classification

Trade and other payables (note 11), excluding VAT and amounts received in advance, are classified as financial liabilities subsequently measured at amortised cost.

Recognition and measurement

They are recognised when the company becomes a party to the contractual provisions, and are measured, at initial recognition, at fair value plus transaction costs, if any.

They are subsequently measured at amortised cost using the effective interest method.

The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or (where appropriate) a shorter period, to the amortised cost of a financial liability.

If trade and other payables contain a significant financing component, and the effective interest method results in the recognition of interest expense, then it is included in profit or loss in finance costs (note 18).

Trade and other payables expose the company to liquidity risk and possibly to interest rate risk. Refer to note 23 for details of risk exposure and management thereof.

Cash and cash equivalents

Cash and cash equivalents are stated at carrying amount which is deemed to be fair value.

Bank overdrafts

Bank overdrafts are initially measured at fair value, and are subsequently measured at amortised cost, using the effective interest rate method.

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Accounting Policies

1.5 Financial instruments (continued)

Derecognition

Financial assets

The company derecognises a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. If the company neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the company recognises its retained interest in the asset and an associated liability for amounts it may have to pay. If the company retains substantially all the risks and rewards of ownership of a transferred financial asset, the company continues to recognise the financial asset and also recognises a collateralised borrowing for the proceeds received.

Financial liabilities

The company derecognises financial liabilities when, and only when, the company obligations are discharged, cancelled or they expire. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognised in profit or loss.

Reclassification

Financial assets

The company only reclassifies affected financial assets if there is a change in the business model for managing financial assets. If a reclassification is necessary, it is applied prospectively from the reclassification date. Any previously stated gains, losses or interest are not restated.

The reclassification date is the beginning of the first reporting period following the change in business model which necessitates a reclassification.

Financial liabilities

Financial liabilities are not reclassified.

1.6 Hedge accounting

1.7 Tax

Current tax assets and liabilities

Current tax for current and prior periods is, to the extent unpaid, recognised as a liability. If the amount already paid in respect of current and prior periods exceeds the amount due for those periods, the excess is recognised as an asset.

Current tax liabilities (assets) for the current and prior periods are measured at the amount expected to be paid to (recovered from) the tax authorities, using the tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets and liabilities

A deferred tax liability is recognised for all taxable temporary differences, except to the extent that the deferred tax liability arises from the initial recognition of an asset or liability in a transaction which at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

A deferred tax asset is recognised for all deductible temporary differences to the extent that it is probable that taxable profit will be available against which the deductible temporary difference can be utilised. A deferred tax asset is not recognised when it arises from the initial recognition of an asset or liability in a transaction at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

A deferred tax asset is recognised for the carry forward of unused tax losses and unused STC credits to the extent that it is probable that future taxable profit will be available against which the unused tax losses and unused STC credits can be utilised.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Accounting Policies

1.7 Tax (continued)

Tax expenses

Current and deferred taxes are recognised as income or an expense and included in profit or loss for the period, except to the extent that the tax arises from:

- a transaction or event which is recognised, in the same or a different period, to other comprehensive income, or
- a business combination.

Current tax and deferred taxes are charged or credited to other comprehensive income if the tax relates to items that are credited or charged, in the same or a different period, to other comprehensive income.

Current tax and deferred taxes are charged or credited directly to equity if the tax relates to items that are credited or charged, in the same or a different period, directly in equity.

1.8 Leases

The company assesses whether a contract is, or contains a lease, at the inception of the contract.

A contract is, or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

In order to assess whether a contract is, or contains a lease, management determine whether the asset under consideration is "identified", which means that the asset is either explicitly or implicitly specified in the contract and that the supplier does not have a substantial right of substitution throughout the period of use. Once management has concluded that the contract deals with an identified asset, the right to control the use thereof is considered. To this end, control over the use of an identified asset only exists when the company has the right to substantially all of the economic benefits from the use of the asset as well as the right to direct the use of the asset.

In circumstances where the determination of whether the contract is or contains a lease requires significant judgement, the relevant disclosures are provided in the significant judgments and sources of estimation uncertainty section of these accounting policies.

Company as lessee

A lease liability and corresponding right-of-use asset are recognised at the lease commencement date, for all lease agreements for which the company is a lessee, except for short-term leases of 12 months or less, or leases of low value assets. For these leases, the company recognises the lease payments as an operating expense (note 16) on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.

The various lease and non-lease components of contracts containing leases are accounted for separately, with consideration being allocated to each lease component on the basis of the relative stand-alone prices of the lease components and the aggregate stand-alone price of the non-lease components (where non-lease components exist).

However as an exception to the preceding paragraph, the company has elected not to separate the non-lease components for leases of land and buildings.

Details of leasing arrangements where the company is a lessee are presented in note 4 Leases (company as lessee).

Lease liability

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the company uses its incremental borrowing rate.

Lease payments included in the measurement of the lease liability comprise the following:

- fixed lease payments, including in-substance fixed payments, less any lease incentives;
- variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date;
- the amount expected to be payable by the company under residual value guarantees;
- the exercise price of purchase options, if the company is reasonably certain to exercise the option;
- lease payments in an optional renewal period if the company is reasonably certain to exercise an extension option; and
- penalties for early termination of a lease, if the lease term reflects the exercise of an option to terminate the lease.

Variable rents that do not depend on an index or rate are not included in the measurement of the lease liability (or right-of-use asset). The related payments are recognised as an expense in the period incurred and are included in operating expenses (note 4).

The lease liability is presented as a separate line item on the Statement of Financial Position.

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Accounting Policies

1.8 Leases (continued)

The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect lease payments made. Interest charged on the lease liability is included in finance costs (note 18).

The company remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) when:

- there has been a change to the lease term, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate;
- there has been a change in the assessment of whether the company will exercise a purchase, termination or extension option, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate;
- there has been a change to the lease payments due to a change in an index or a rate, in which case the lease liability is remeasured by discounting the revised lease payments using the initial discount rate (unless the lease payments change is due to a change in a floating interest rate, in which case a revised discount rate is used);
- there has been a change in expected payment under a residual value guarantee, in which case the lease liability is remeasured by discounting the revised lease payments using the initial discount rate;
- a lease contract has been modified and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured by discounting the revised payments using a revised discount rate.

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recognised in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

Right-of-use assets

Right-of-use assets are presented as a separate line item on the Statement of Financial Position.

Lease payments included in the measurement of the lease liability comprise the following:

- the initial amount of the corresponding lease liability;
- any lease payments made at or before the commencement date;
- any initial direct costs incurred;
- any estimated costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, when the company incurs an obligation to do so, unless these costs are incurred to produce inventories; and
- less any lease incentives received.

Right-of-use assets are subsequently measured at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. However, if a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. Depreciation starts at the commencement date of a lease.

For right-of-use assets which are depreciated over their useful lives, the useful lives are determined consistently with items of the same class of property, plant and equipment. Refer to the accounting policy for property, plant and equipment for details of useful lives.

The residual value, useful life and depreciation method of each asset are reviewed at the end of each reporting year. If the expectations differ from previous estimates, the change is accounted for prospectively as a change in accounting estimate. Each part of a right-of-use asset with a cost that is significant in relation to the total cost of the asset is depreciated separately.

The depreciation charge for each year is recognised in profit or loss unless it is included in the carrying amount of another asset.

1.9 Inventories

Inventories are measured at the lower of cost and net realisable value.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

The cost of inventories comprises of all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.

The cost of inventories of items that are not ordinarily interchangeable and goods or services produced and segregated for specific projects is assigned using specific identification of the individual costs.

The cost of inventories is assigned using the weighted average cost formula. The same cost formula is used for all inventories having a similar nature and use to the entity.

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Accounting Policies

1.9 Inventories (continued)

When inventories are sold, the carrying amount of those inventories are recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of inventories to net realisable value and all losses of inventories are recognised as an expense in the period the write-down or loss occurs. The amount of any reversal of any write-down of inventories, arising from an increase in net realisable value, are recognised as a reduction in the amount of inventories recognised as an expense in the period in which the reversal occurs.

Inventories includes a "right to returned goods asset" which represents the company right to recover products from customers where customers exercise their right of return under the company returns policy. The company uses its accumulated historical experience to estimate the number of returns on a portfolio level using the expected value method. A corresponding adjustment is recognised against cost of sales.

1.10 Impairment of assets

The company assesses at each end of the reporting period whether there is any indication that an asset may be impaired. If any such indication exists, the company estimates the recoverable amount of the asset.

Irrespective of whether there is any indication of impairment, the company also:

- tests intangible assets with an indefinite useful life or intangible assets not yet available for use for impairment annually by comparing its carrying amount with its recoverable amount. This impairment test is performed during the annual period and at the same time every period.
- tests goodwill acquired in a business combination for impairment annually.

If there is any indication that an asset may be impaired, the recoverable amount is estimated for the individual asset. If it is not possible to estimate the recoverable amount of the individual asset, the recoverable amount of the cash-generating unit to which the asset belongs is determined.

The recoverable amount of an asset or a cash-generating unit is the higher of its fair value less costs to sell and its value in use.

If the recoverable amount of an asset is less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. That reduction is an impairment loss.

An impairment loss of assets carried at cost less any accumulated depreciation or amortisation is recognised immediately in profit or loss. Any impairment loss of a revalued asset is treated as a revaluation decrease.

An entity assesses at each reporting date whether there is any indication that an impairment loss recognised in prior periods for assets other than goodwill may no longer exist or may have decreased. If any such indication exists, the recoverable amounts of those assets are estimated.

The increased carrying amount of an asset other than goodwill attributable to a reversal of an impairment loss does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior periods.

A reversal of an impairment loss of assets carried at cost less accumulated depreciation or amortisation other than goodwill is recognised immediately in profit or loss. Any reversal of an impairment loss of a revalued asset is treated as a revaluation increase.

1.11 Share capital and equity

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities.

Ordinary shares are recognised at par value and classified as 'share capital' in equity. Any amounts received from the issue of shares in excess of par value is classified as 'share premium' in equity. Dividends are recognised as a liability in the company in which they are declared.

1.12 Employee benefits

Short-term employee benefits

The cost of short-term employee benefits, (those payable within 12 months after the service is rendered, such as paid vacation leave and sick leave, bonuses, and non-monetary benefits such as medical care), are recognised in the period in which the service is rendered and are not discounted.

The expected cost of compensated absences is recognised as an expense as the employees render services that increase their entitlement or, in the case of non-accumulating absences, when the absence occurs.

The expected cost of profit sharing and bonus payments is recognised as an expense when there is a legal or constructive obligation to make such payments as a result of past performance.

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Accounting Policies

1.12 Employee benefits (continued)

Defined contribution plans

Payments to defined contribution retirement benefit plans are charged as an expense as they fall due.

Payments made to industry-managed (or state plans) retirement benefit schemes are dealt with as defined contribution plans where the company's obligation under the schemes is equivalent to those arising in a defined contribution retirement benefit plan.

1.13 Revenue from contracts with customers

The company recognises revenue from the following major sources:

- Sales of sports goods

Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties. The company recognises revenue when it transfers control of a product or service to a customer.

1.14 Cost of sales

When inventories are sold, the carrying amount of those inventories is recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of inventories to net realisable value and all losses of inventories are recognised as an expense in the period the write-down or loss occurs. The amount of any reversal of any write-down of inventories, arising from an increase in net realisable value, is recognised as a reduction in the amount of inventories recognised as an expense in the period in which the reversal occurs.

The related cost of providing services recognised as revenue in the current period is included in cost of sales.

Cost of sales is reduced by the amount recognised in inventory as a "right to returned goods asset" which represents the company right to recover products from customers where customers exercise their right of return under the company returns policy.

1.15 Translation of foreign currencies

Foreign currency transactions

A foreign currency transaction is recorded, on initial recognition in Rands, by applying to the foreign currency amount the spot exchange rate between the functional currency and the foreign currency at the date of the transaction.

At the end of the reporting period:

- foreign currency monetary items are translated using the closing rate;
- non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction; and
- non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined.

In circumstances where the company receives or pays an amount in foreign currency in advance of a transaction, the transaction date for purposes of determining the exchange rate to use on initial recognition of the related asset, income or expense is the date on which the company initially recognised the non-monetary item arising on payment or receipt of the advance consideration.

If there are multiple payments or receipts in advance, company determines a date of transaction for each payment or receipt of advance consideration.

Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements are recognised in profit or loss in the period in which they arise.

Cash flows arising from transactions in a foreign currency are recorded in Rands by applying to the foreign currency amount the exchange rate between the Rand and the foreign currency at the date of the cash flow.

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

2. New Standards and Interpretations

2.1 Standards and interpretations effective and adopted in the current year

In the current year, the company has adopted the following standards and interpretations that are effective for the current financial year and that are relevant to its operations:

Standard/ Interpretation:	Effective date: Years beginning on or after	Expected impact:
<ul style="list-style-type: none">Interest Rate Benchmark Reform - Phase 2: Amendments to IFRS 7	01 January 2021	The impact of the amendments is not material.
<ul style="list-style-type: none">Interest Rate Benchmark Reform - Phase 2: Amendments to IFRS 9	01 January 2021	The impact of the amendments is not material.

2.2 Standards and interpretations not yet effective

The company has chosen not to early adopt the following standards and interpretations, which have been published and are mandatory for the company's accounting periods beginning on or after 01 April 2022 or later periods:

Standard/ Interpretation:	Effective date: Years beginning on or after	Expected impact:
<ul style="list-style-type: none">Deferred tax related to assets and liabilities arising from a single transaction - Amendments to IAS 12	01 January 2023	Unlikely there will be a material impact
<ul style="list-style-type: none">Disclosure of accounting policies: Amendments to IAS 1 and IFRS Practice Statement 2.	01 January 2023	Unlikely there will be a material impact
<ul style="list-style-type: none">Definition of accounting estimates: Amendments to IAS 8	01 January 2023	Unlikely there will be a material impact
<ul style="list-style-type: none">Classification of Liabilities as Current or Non-Current - Amendment to IAS 1	01 January 2023	Unlikely there will be a material impact
<ul style="list-style-type: none">Annual Improvement to IFRS Standards 2018-2020: Amendments to IFRS 1	01 January 2022	Unlikely there will be a material impact
<ul style="list-style-type: none">Annual Improvement to IFRS Standards 2018-2020: Amendments to IFRS 9	01 January 2022	Unlikely there will be a material impact
<ul style="list-style-type: none">Property, Plant and Equipment: Proceeds before Intended Use: Amendments to IAS 16	01 January 2022	Unlikely there will be a material impact

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

3. Property, plant and equipment

	2022			2021		
	Cost	Accumulated depreciation	Carrying value	Cost	Accumulated depreciation	Carrying value
Land	16 976 500	-	16 976 500	16 976 500	-	16 976 500
Machinery	279 178 527	(239 508 121)	39 670 406	263 379 675	(231 793 089)	31 586 586
Fixtures and fittings	7 791 621	(7 533 729)	257 892	7 791 621	(7 460 143)	331 478
Motor vehicles	1 299 362	(939 408)	359 954	1 299 362	(820 042)	479 320
Office equipment	803 293	(716 015)	87 278	802 250	(708 166)	94 084
Computer equipment	3 924 333	(3 296 717)	627 616	3 610 383	(2 837 971)	772 412
Leasehold improvements	127 144 303	(111 255 477)	15 888 826	124 580 423	(110 832 155)	13 748 268
Capital - Work in progress	(6 739 278)	9 228 925	2 489 647	4 021 231	7 237 929	11 259 160
Total	430 378 661	(354 020 542)	76 358 119	422 461 445	(347 213 637)	75 247 808

Reconciliation of property, plant and equipment - 2022

	Opening balance	Additions	Transfers	Depreciation	Total
Land	16 976 500	-	-	-	16 976 500
Machinery	31 586 586	617 259	15 181 593	(7 715 032)	39 670 406
Fixtures and fittings	331 478	-	-	(73 586)	257 892
Motor vehicles	479 320	-	-	(119 366)	359 954
Office equipment	94 084	1 043	-	(7 849)	87 278
Computer equipment	772 412	313 950	-	(458 746)	627 616
Leasehold improvements	13 748 268	2 563 881	-	(423 323)	15 888 826
Capital - Work in progress	11 259 160	6 412 080	(15 181 593)	-	2 489 647
	75 247 808	9 908 213	-	(8 797 902)	76 358 119

Reconciliation of property, plant and equipment - 2021

	Opening balance	Additions	Depreciation	Total
Land	16 420 902	555 598	-	16 976 500
Machinery	35 261 364	2 864 283	(6 539 061)	31 586 586
Fixtures and fittings	338 536	63 238	(70 296)	331 478
Motor vehicles	598 686	-	(119 366)	479 320
Office equipment	70 196	29 648	(5 760)	94 084
Computer equipment	880 523	292 219	(400 330)	772 412
Leasehold improvements	7 970 052	5 965 932	(187 716)	13 748 268
Capital - Work in progress	518 860	10 740 300	-	11 259 160
	62 059 119	20 511 218	(7 322 529)	75 247 808

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

	2022 R	2021 R
4. Leases (company as lessee)		
The company has the option to purchase the plant at a nominal amount on completion of the lease term.		
Details pertaining to leasing arrangements, where the company is lessee are presented below:		
Net carrying amounts of right-of-use assets		
The carrying amounts of right-of-use assets are included in the following line items:		
Buildings	1 960 492	2 495 172
Additions to right-of-use assets		
Buildings	-	2 673 398
Depreciation recognised on right-of-use assets		
Depreciation recognised on each class of right-of-use assets, is presented below. It includes depreciation which has been expensed in the total depreciation charge in profit or loss (note 16), as well as depreciation which has been capitalised to the cost of other assets.		
Buildings	534 680	178 226
Other disclosures		
Leases of low value assets included in operating expenses	1 127 791	654 540
Total cash outflow from leases	(618 744)	(314 480)
Lease liabilities		
The maturity analysis of lease liabilities is as follows:		
Within one year	478 622	412 148
Two to five years	1 655 936	2 134 560
	2 134 558	2 546 708
Non-current liabilities	1 655 936	2 134 560
Current liabilities	478 622	412 148
	2 134 558	2 546 708

5. Intangible assets

	2022			2021		
	Cost	Accumulated amortisation	Carrying value	Cost	Accumulated amortisation	Carrying value
Copyrights, patents and other industrial property rights	188 408	-	188 408	188 408	-	188 408
Computer software	822 753	(561 202)	261 551	781 356	(510 970)	270 386
Total	1 011 161	(561 202)	449 959	969 764	(510 970)	458 794

Reconciliation of intangible assets - 2022

	Opening balance	Additions	Amortisation	Total
Copyrights, patents and other industrial property rights	188 408	-	-	188 408
Computer software	270 386	41 397	(50 232)	261 551
	458 794	41 397	(50 232)	449 959

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

	2022 R	2021 R
--	-----------	-----------

5. Intangible assets (continued)

Reconciliation of intangible assets - 2021

	Opening balance	Amortisation	Total
Copyrights, patents and other industrial property rights	188 408	-	188 408
Computer software	344 673	(74 287)	270 386
	533 081	(74 287)	458 794

6. Deferred tax

During the current year, there had been no provision made for income tax as the entity had no taxable income. The estimated tax loss available for set off against future taxable income is R225 791 483 (2021: R296 372 791).

7. Inventories

Raw materials	177 246 913	166 262 050
Work in progress	11 419 807	10 239 237
Finished goods	219 564 129	277 252 522
Merchandise	35 244 497	85 665 875
	443 475 346	539 419 684

Inventories of R65 310 457 were written down to net realisable value during the current year (2021: R19 273 820).

8. Trade and other receivables

Financial instruments:

Trade receivables	304 257 764	409 239 885
Loss allowance	(13 945 488)	(22 206 790)
Trade receivables at amortised cost	290 312 276	387 033 095
Sundry debtors	131 170	201 170

Non-financial instruments:

Value added tax	2 932 372	9 953 614
Employee costs in advance	396 050	46 000
Prepayments	1 716 605	1 275 528

Total trade and other receivables

295 488 473 398 509 407

Split between non-current and current portions

Current assets	295 488 473	398 509 407
----------------	-------------	-------------

Financial instrument and non-financial instrument components of trade and other receivables

At amortised cost	290 443 446	387 234 265
Non-financial instruments	5 045 027	11 275 142
	295 488 473	398 509 407

Exposure to credit risk

Trade receivables inherently expose the company to credit risk, being the risk that the company will incur financial loss if customers fail to make payments as they fall due.

A loss allowance is recognised for all trade receivables, in accordance with IFRS 9 Financial Instruments, and is monitored at the end of each reporting period. In addition to the loss allowance, trade receivables are written off when there is no reasonable expectation of recovery, for example, when a debtor has been placed under liquidation. Trade receivables which have been written off are not subject to enforcement activities.

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

2022
R

2021
R

8. Trade and other receivables (continued)

A forward looking allowance for expected credit losses is recognised for all debt instruments not held at fair value through profit or loss. Expected credit losses are based on the difference between contractual cash flows due in accordance with the contract and all the cash flows that the company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

For trade receivables and contract assets, a simplified approach is applied in calculating expected credit losses. Instead of tracking changes in credit risk, a loss allowance is recognised based on lifetime expected credit losses at each reporting date. A provision matrix was established that is based on the company's historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

The company's historical credit loss experience does not show significantly different loss patterns for different customer segments. The provision for credit losses is therefore based on past due status without disaggregating into further risk profiles. The loss allowance provision is determined as follows:

	2022	2022	2021	2021
	Estimated gross carrying amount at default	Loss allowance (Lifetime expected credit loss)	Estimated gross carrying amount at default	Loss allowance (Lifetime expected credit loss)
Expected credit loss rate:				
Not past due	227 447 550	-	296 090 251	-
31 - 60 days past due	35 670 959	-	42 919 391	-
61 - 90 days past due	10 120 569	-	21 500 566	-
91 - 120 days past due	5 750 023	-	5 744 408	-
More than 120 days past due	25 268 663	13 945 488	17 778 770	22 206 790
Total	304 257 764	13 945 488	384 033 386	22 206 790

Reconciliation of loss allowances

The following table shows the movement in the loss allowance (lifetime expected credit losses) for lease receivables:

Opening balance	(22 206 790)	(28 535 565)
Amounts recovered	8 261 302	6 328 775
Closing balance	(13 945 488)	(22 206 790)

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

	2022 R	2021 R
9. Cash and cash equivalents		
Cash and cash equivalents consist of:		
Cash on hand	657	1 663
Bank balances	190 592 216	98 665 503
	190 592 873	98 667 166
10. Share capital		
Authorised		
1 000 Ordinary shares of R1 each	1 000	1 000
Issued		
Ordinary	200 000 200	200 000 200
Redeemable preference shares	500 000 000	500 000 000
	700 000 200	700 000 200
11. Trade and other payables		
Financial instruments:		
Trade payables	66 172 200	106 911 020
Trade payables - related parties	398 198 329	497 075 903
Other payables and accruals	1 489 780	1 513 992
Non-financial instruments:		
Payroll accruals	(58 248)	228 765
Marketing accruals	60 307 703	80 423 991
	526 109 764	686 153 671
Creditors and accruals principally comprise amounts outstanding for trade purchases and ongoing costs. The average credit period taken is less than 60 days. No interest is charged on trade payables. The company and the group have risk management policies in place to ensure that all payables are paid within the agreed credit terms. The carrying amount of financial liabilities approximates its fair values.		
Financial instrument and non-financial instrument components of trade and other payables		
At amortised cost	465 860 309	605 500 915
Non-financial instruments	60 249 455	80 652 756
	526 109 764	686 153 671
12. Revenue		
Revenue from contracts with customers		
Sale of goods	1 399 830 554	1 171 245 545
Disaggregation of revenue from contracts with customers		
The company disaggregates revenue from customers as follows:		
Sale of goods		
Sale of goods	1 399 830 554	1 171 245 545
Timing of revenue recognition		
At a point in time		
Sale of goods	1 399 830 554	1 171 245 545

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

	2022 R	2021 R
13. Cost of sales		
Sale of goods	1 079 017 648	856 104 960
14. Other operating income		
Insurance claim received	10 843	-
Other income	10 682 062	3 938 696
	10 692 905	3 938 696
15. Other operating gains (losses)		
Foreign exchange gains (losses)		
Net foreign exchange (losses) gains	(752 430)	2 078 811
16. Operating profit (loss)		
Operating profit for the year is stated after charging (crediting) the following, amongst others:		
Auditor's remuneration	955 808	1 847 068
Remuneration, other than to employees		
Consulting and professional services	2 501 697	2 512 453
Employee costs		
Salaries, wages, bonuses and other benefits	144 561 856	145 771 766
Short-term benefit 1	5 973 153	7 708 378
Retirement benefit plans: defined contribution expense	5 817 082	5 827 329
Total employee costs	156 352 091	159 307 473
Leases		
Leases of low value assets	1 127 791	654 540
Total lease expenses	1 127 791	654 540
Depreciation and amortisation		
Depreciation of property, plant and equipment	8 396 890	7 322 529
Depreciation of right-of-use assets	534 680	178 226
Amortisation of intangible assets	451 243	252 514
Total depreciation and amortisation	9 382 813	7 753 269
Expenses by nature		
The total cost of sales, selling and distribution expenses, marketing expenses, general and administrative expenses, research and development expenses, maintenance expenses and other operating expenses are analysed by nature as follows:		
Changes in inventories of finished goods and work in progress	1 079 017 648	856 104 960
Employee costs	156 352 091	159 307 473
Lease expenses	1 127 791	654 540
Depreciation, amortisation and impairment	9 382 813	7 753 269
Other expenses	111 769 845	124 608 181
	1 357 650 188	1 148 428 423

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

	2022 R	2021 R
17. Investment income		
Interest income		
Investments in financial assets:		
Bank and other cash	2 248 391	1 899 218
18. Finance costs		
Other interest paid	385 941	1 681
19. Taxation		
Reconciliation of the tax expense		
Reconciliation between applicable tax rate and average effective tax rate.		
Applicable tax rate	28,00 %	28,00 %
Assessed loss	(28,00)%	(28,00)%
	- %	- %
No provision has been made for 2022 tax as the company has no taxable income. The estimated tax loss available for set off against future taxable income is R 225 791 483 (2021: R 296 372 691).		
20. Cash generated from operations		
Profit before taxation	53 983 291	30 732 166
Adjustments for:		
Depreciation and amortisation	9 382 813	7 753 269
Interest income	(2 248 391)	(1 899 218)
Finance costs	385 941	1 681
Changes in working capital:		
Inventories	95 944 338	(174 126 283)
Trade and other receivables	103 020 934	(202 768 202)
Trade and other payables	(160 043 909)	402 693 787
	100 425 017	62 387 200

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

	2022 R	2021 R
21. Related parties		
Relationships		
Ultimate holding company		Sun Pharmaceutical Industries Limited
Holding company		Sun Pharma (Netherlands) BV
Fellow subsidiaries		Sonke Pharmaceuticals Proprietary Limited
Sister company		Ranbaxy South Africa Proprietary Limited
		Sun Pharmaceuticals SA Proprietary Limited
Members of key management		Desmond William Brothers (Director)
		Umesh Kumar Maini (Director)
		Avesh Ajoodha (Director)
		Deepakh Mangal Sewnarain (Director)
Related party balances		
Amounts included in trade receivables regarding related parties		
Sonke Pharmaceuticals Proprietary Limited	55 532 655	75 204 057
Sun Pharmaceuticals SA Proprietary Limited	49 956 511	47 972 107
Sun Pharmaceutical Industries Limited	33 352 340	33 352 340
Ranbaxy South Africa Proprietary Limited	384 794	-
	139 226 300	156 528 504
Amounts included in trade payables regarding related parties		
Ranbaxy South Africa Proprietary Limited	(37 466 418)	(80 774 196)
Sonke Pharmaceuticals Proprietary Limited	(45 240 968)	(8 980 897)
Sun Pharmaceuticals SA Proprietary Limited	(49 712 522)	(56 294 994)
Sun Pharmaceutical Industries Limited	(296 258 822)	(419 130 660)
	(428 678 730)	(565 180 747)
Related party transactions		
Sales to related parties		
Sonke Pharmaceuticals Proprietary Limited	304 568 158	424 802 740
Purchases from related parties		
Sun Pharmaceuticals SA Proprietary Limited	(2 545 487)	(22 046 092)
Sun Pharmaceutical Industries Limited	(697 441 441)	(806 076 892)
Sun Pharmaceuticals Industries (Australia) Pty Ltd	(1 261 874)	(108 534)
Ranbaxy South Africa Proprietary Limited	(13 436 004)	-
	(714 684 806)	(828 231 518)
Royalties received from related parties		
Sonke pharmaceuticals Proprietary Limited	12 070 088	-
Management fee cross charges between related parties		
Ranbaxy South Africa Proprietary Limited	54 952 905	-

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

	2022 R	2021 R		
22. Directors' emoluments				
Executive				
2022				
Directors' emoluments	Basic salary	Bonuses and performance related payments	Pensions receivable or received	Total
Services as director or prescribed officer				
Person A	3 199 416	691 843	430 340	4 321 599
Person D	1 603 441	260 744	160 995	2 025 180
Director F	1 491 163	246 376	195 307	1 932 846
Director J	4 187 857	636 880	388 672	5 213 409
	10 481 877	1 835 843	1 175 314	13 493 034
2021				
Directors' emoluments	Basic salary	Bonuses and performance related payments	Pensions receivable or received	Total
Services as director or prescribed officer				
Person A	2 994 326	673 712	408 878	4 076 916
Person D	1 510 171	221 942	151 957	1 884 070
Director F	1 293 303	214 949	174 691	1 682 943
Director J	4 221 456	628 969	376 747	5 227 172
	10 019 256	1 739 572	1 112 273	12 871 101

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

	2022 R	2021 R
--	-----------	-----------

23. Financial instruments and risk management

Categories of financial instruments

Categories of financial assets

2022

	Note(s)	Amortised cost	Total
Trade and other receivables	8	290 443 446	290 443 446
Cash and cash equivalents	9	190 592 873	190 592 873
		481 036 319	481 036 319

2021

	Note(s)	Amortised cost	Total
Trade and other receivables	8	387 234 265	387 234 265
Cash and cash equivalents	9	98 667 166	98 667 166
		485 901 431	485 901 431

Categories of financial liabilities

2022

	Note(s)	Amortised cost	Leases	Total
Trade and other payables	11	465 860 309	-	465 860 309
Finance lease obligations	4	-	2 134 558	2 134 558
		465 860 309	2 134 558	467 994 867

2021

	Note(s)	Amortised cost	Leases	Total
Trade and other payables	11	605 500 919	-	605 500 919
Finance lease obligations	4	-	2 546 708	2 546 708
		605 500 919	2 546 708	608 047 627

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

		2022	2021
		R	R
23. Financial instruments and risk management (continued)			
Capital risk management			
The company's objective when managing capital (which includes share capital, borrowings, working capital and cash and cash equivalents) is to maintain a flexible capital structure that reduces the cost of capital to an acceptable level of risk and to safeguard the company's ability to continue as a going concern while taking advantage of strategic opportunities in order to maximise stakeholder returns sustainably.			
The company manages capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain the capital structure, the company may adjust the amount of dividends paid to the shareholder, return capital to the shareholder, repurchase shares currently issued, issue new shares, issue new debt, issue new debt to replace existing debt with different characteristics and/or sell assets to reduce debt.			
The company monitors capital utilising a number of measures, including the gearing ratio. The gearing ratio is calculated as net borrowings (total borrowings less cash) divided by shareholders' equity.			
The capital structure and gearing ratio of the company at the reporting date was as follows:			
Lease liabilities		2 134 558	2 546 708
Trade and other payables	11	526 109 764	686 153 675
Total borrowings		528 244 322	688 700 383
Cash and cash equivalents	9	(190 592 873)	(98 667 166)
Net borrowings		337 651 449	590 033 217
Equity		480 080 940	426 097 649

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

2022
R

2021
R

23. Financial instruments and risk management (continued)

Financial risk management

Overview

The company is exposed to the following risks from its use of financial instruments:

- Credit risk;
- Liquidity risk; and
- Market risk (currency risk, interest rate risk and price risk).

The board of directors has overall responsibility for the establishment and oversight of the company's risk management framework. The board has established the risk committee, which is responsible for developing and monitoring the company's risk management policies. The committee reports quarterly to the board of directors on its activities.

Credit risk

Credit risk is the risk of financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations.

The company is exposed to credit risk on loans receivable (at amortised cost), debt instruments at fair value through other comprehensive income, trade and other receivables, contract receivables, lease receivables, cash and cash equivalents, loan commitments and financial guarantees.

Credit risk exposure arising on cash and cash equivalents is managed by the group through dealing with well-established financial institutions with high credit ratings.

Credit loss allowances for expected credit losses are recognised for all debt instruments, but excluding those measured at fair value through profit or loss. Credit loss allowances are also recognised for loan commitments and financial guarantee contracts.

The maximum exposure to credit risk is presented in the table below:

		2022			2021		
		Gross carrying amount	Credit loss allowance	Amortised cost / fair value	Gross carrying amount	Credit loss allowance	Amortised cost / fair value
Trade and other receivables	8	309 433 961	(13 945 488)	295 488 473	420 716 197	(22 206 790)	398 509 407
Cash and cash equivalents	9	190 592 873	-	190 592 873	98 667 166	-	98 667 166
		500 026 834	(13 945 488)	486 081 346	519 383 363	(22 206 790)	497 176 573

Liquidity risk

The maturity profile of contractual cash flows of non-derivative financial liabilities, and financial assets held to mitigate the risk, are presented in the following table. The cash flows are undiscounted contractual amounts.

2022

		Less than 1 year	Total	Carrying amount
Non-current liabilities				
Lease liabilities		-	-	1 655 936
Current liabilities				
Trade and other payables	11	465 860 309	465 860 309	465 860 309
Lease liabilities		-	-	478 622
Bank overdraft	9	191 886 207	191 886 207	191 886 207
		448 246 105	657 746 516	659 881 074

2021

Ranbaxy Pharmaceuticals Proprietary Limited

(Registration number 1993/003111/07)

Financial Statements for the year ended 31 March 2022

Notes to the Financial Statements

			2022 R	2021 R	
23. Financial instruments and risk management (continued)					
		Less than 1 year	2 to 5 years	Total	Carrying amount
Non-current liabilities					
Lease liabilities		-	2 134 560	2 134 560	2 134 560
Current liabilities					
Trade and other payables	11	605 500 919	-	605 500 919	605 500 919
Lease liabilities		412 148	-	412 148	412 148
		605 913 067	2 134 560	608 047 627	608 047 627

Foreign currency risk

The company is exposed to foreign currency risk as a result of certain transactions and borrowings which are denominated in foreign currencies. Exchange rate exposures are managed within approved policy parameters utilising foreign forward exchange contracts where necessary. The foreign currencies in which the company deals primarily are US Dollars, Euros and Yen.

There have been no significant changes in the foreign currency risk management policies and processes since the prior reporting period.

Exposure in Rand

The net carrying amounts, in Rand, of the various exposures, are denominated in the following currencies. The amounts have been presented in Rand by converting the foreign currency amounts at the closing rate at the reporting date:

Exposure

Current liabilities:

Trade and other payables BWP 32 360 (2021: BWP Nil)	11	41 270	-
Trade and other payables USD 243 746 (2021: USD Nil)	9	(3 543 763)	-
Net exposure		(3 502 493)	-

Exchange rates

Foreign currency per Rand

BWP	1,275	-
USD	14,570	-

24. Going concern

The financial statements have been prepared on the basis of accounting policies applicable to a going concern. This basis presumes that funds will be available to finance future operations and that the realisation of assets and settlement of liabilities, contingent obligations and commitments will occur in the ordinary course of business.

The directors believe that the company has adequate financial resources to continue in operation for the foreseeable future and accordingly the financial statements have been prepared on a going concern basis. The directors have satisfied themselves that the company is in a sound financial position and that it has access to sufficient borrowing facilities to meet its foreseeable cash requirements. The directors are not aware of any new material changes that may adversely impact the company. The director directors are also not aware of any material non-compliance with statutory or regulatory requirements or of any pending changes to legislation which may affect the company.

25. Events after the reporting period

The directors are not aware of any material event which occurred after the reporting date and up to the date of this report.